Pressure-dependent, enhanced natriuretic response to low-dose, atrial natriuretic peptide infusion in essential hypertension

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

To examine whether the effect of atrial natriuretic peptide (ANP) on renal glomerular and tubular segmental handling of sodium in patients with essential hypertension is pressure dependent.

Who Took Part

The study group was 13 subjects.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some subjects received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.

The results were compared with those obtained during infusion with ANP+placebo (Part 1).

Lithium clearance was used to estimate the proximal tubular reabsorption of sodium.

What Was Measured

PubMed files the paper under topics including Aldosterone, Angiotensin II, Arginine Vasopressin, Atrial Natriuretic Factor, Blood Pressure, Case-Control Studies and Hypertension.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 13 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1994 (Journal of internal medicine), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.